Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of tusamitamab ravtansine with pembrolizumab with or without platinum-based chemotherapy in CEACAM5-positive non-squamous NSCLC
MOH_2020-12-21_009591Phase 2Recruiting
- Sponsor
- Sanofi
- Start
- Aug 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of tusamitamab ravtansine in Non-small cell lung cancer (NS-NSCLC) (5 arms), sponsored by Sanofi. Primary endpoints: Safety and tolerability and Recommended combination dose. Started Aug 2020; status: recruiting.
02
Drugs
tusamitamab ravtansine
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on MOH_2020-12-21_009591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-12-21_009591.